At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 424 enrolled
Drug / intervention
Dulaglutide +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating Dulaglutide, Placebo, and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 424 participants across 41 sites in 9 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesAustria, Czechia, Germany, Hungary, Israel, Mexico, Puerto Rico, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartNov 2015
First PostedNov 2015
Primary CompletionFeb 2017
TodayJul 2026
First PostedNov 4, 2015
Enrollment StartNov 1, 2015
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.7 years ago
Interventions
Dulaglutidedrug
Administered SC
Placebodrug
Administered SC
SGLT2 inhibitordrug
Administered orally as standard of care for type 2 diabetes
Metformindrug
Administered orally as standard of care for type 2 diabetes